Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives

Immune checkpoint inhibition (ICI) became one of the major breakthroughs in cancer treatment over the past decade and entered into therapy within standard oncohematology practice. ICI has demonstrated impressive response rates as salvage therapy in relapsed/refractory (R/R) classical Hodgkin lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: De Goycoechea, Diego, Stalder, Gregoire, Martins, Filipe, Duchosal, Michel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530161/
https://www.ncbi.nlm.nih.gov/pubmed/31205470
http://dx.doi.org/10.1155/2019/9513701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530161/
https://www.ncbi.nlm.nih.gov/pubmed/31205470
http://dx.doi.org/10.1155/2019/9513701

Ejemplares similares